Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cabaletta Bio, Inc.

NASDAQ: CABA · Life Sciences · 4 alerts · CIK 1759138

Share price
$1.11Close, Nov 16
Market cap
$239M
Shares outstanding
215.72MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cabaletta Bio, Inc. filings on SEC EDGAR ↗

7:35 AM ET 10-Q
Financial Results

Cabaletta Bio Q3 2026 Results: Net Loss of $53.1M, Loss Widens

Cabaletta Bio is a late-stage clinical biotechnology company focused on autoimmune diseases, specifically advancing its Phase 1/2 RESET clinical trials for rese-cel. As of October 30, 2026, the company reported 215,720,392 shares of common stock outstanding and continues to incur significant losses to fund its R&D and manufacturing partnerships with Lonza and Cellares.

Key figure
Net loss $53.1M
7:31 AM ET 8-K
Financial Results

Cabaletta Bio Financial Results

Cabaletta Bio reported third quarter 2026 financial results, highlighting a cash position of $299.4 million which extends its operational runway into Q1 2028. The company announced plans for a BLA submission for rese-cel in myositis in Q1 2028 and initiated a second registrational study in systemic sclerosis. Management noted a recent increase in enrollment activity following a slower period in Q3 2026.

Term
Q3 2026

“We are encouraged by the favorable benefit-risk profile observed with rese-cel to date as we made deliberate choices, including construct design, standard and well-characterized manufacturing, and weight-based dosing, from the outset of its development to prioritize patient safety.”

Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta

“We are now seeing increased enrollment and screening activity, with multiple patients enrolled in the past few weeks in the registrational adult myositis study, after a slower period in 3Q26 that we believe was influenced by patient and physician caution following recently reported safety events from others in the field.”

Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.